<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04842942</url>
  </required_header>
  <id_info>
    <org_study_id>19-5679</org_study_id>
    <nct_id>NCT04842942</nct_id>
  </id_info>
  <brief_title>The Safety and Feasibility of Transoral Endoscopic Thyroidectomy Vestibular Approach</brief_title>
  <official_title>The Safety and Feasibility of Transoral Endoscopic Thyroidectomy Vestibular Approach</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single center, prospective case series designed to assess the safety and&#xD;
      feasibility of TOETVA in a small cohort of patients at University Health Network Toronto.&#xD;
      Included patients will undergo a TOETVA-procedure in stead of the standard open surgical&#xD;
      procedure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Type of Study This is a single center, prospective case series&#xD;
&#xD;
      Sample Size Since this is a feasibility study we will first include 15 patients. If we find&#xD;
      the TOETVA a safe and feasible approach, we will perform the same study in more patients&#xD;
      using the results of this study for a power size calculation.&#xD;
&#xD;
      Study Population Patients (&gt; 18 years) undergoing (para)thyroid surgery for the indication of&#xD;
      a benign or indeterminate thyroid nodule, well differentiated papillary thyroid carcinoma,&#xD;
      well-controlled Grave's disease or a parathyroid adenoma.&#xD;
&#xD;
      Study Design This is a single center, prospective case series designed to assess the safety&#xD;
      and feasibility of TOETVA in a small cohort of patients at University Health Network Toronto.&#xD;
      Included patients will undergo a TOETVA-procedure in stead of the standard open surgical&#xD;
      procedure.&#xD;
&#xD;
      Study Intervention The study intervention in this study is the TOETVA-procedure. This is an&#xD;
      Transoral Endoscopic Thyroidectomy Vestibular Approach.&#xD;
&#xD;
      Primary Objective The study objective is to assess the safety and feasibility of this&#xD;
      procedure in a small cohort of patients at University Health Network Toronto, Ontario.&#xD;
&#xD;
      Endpoints of the study The main study endpoints consist of&#xD;
&#xD;
        1. Surgical Outcomes: rate of post-operative recurrent laryngeal nerve palsy, rate of&#xD;
           post-operative hypocalcemia, and rate of neck incision (conversion to open), oral&#xD;
           infections, neck infection, hematoma, seroma, subcutaneous emphysema, gas-induced&#xD;
           embolism, surgical time, and length of stay.&#xD;
&#xD;
        2. Quality of Life - EORTC Thyroid specific Health related quality of life&#xD;
&#xD;
      These endpoints will be compared to historical age/indication controls for analysis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2019</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>The study intervention in this study is the TOETVA-procedure. This is an Transoral Endoscopic Thyroidectomy Vestibular Approach.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-operative recurrent laryngeal nerve palsy</measure>
    <time_frame>12 months</time_frame>
    <description>Number of participants with post-operative recurrent laryngeal nerve palsy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative hypocalcemia</measure>
    <time_frame>12 months</time_frame>
    <description>Number of participants with postoperative hypocalcemia</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neck incision</measure>
    <time_frame>1 month</time_frame>
    <description>Number of conversions to open</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of oral infections</measure>
    <time_frame>12 months</time_frame>
    <description>Number of participants with oral infections</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of hematoma</measure>
    <time_frame>1 month</time_frame>
    <description>Number of participants with hematomas</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of seroma</measure>
    <time_frame>1 month</time_frame>
    <description>Number of participants with seromas</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of neck infection</measure>
    <time_frame>12 months</time_frame>
    <description>Number of participants with neck infections</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of subcutaneous emphysema</measure>
    <time_frame>12 months</time_frame>
    <description>Number of participants with subcutaneous emphysema</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of gas-induced embolism</measure>
    <time_frame>12 months</time_frame>
    <description>Number of participants with gas-induced embolism</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Surgical time</measure>
    <time_frame>until surgical discharge, average of 24 hours</time_frame>
    <description>Surgical time in hours</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Length of stay</measure>
    <time_frame>until surgical discharge, average of 24 hours</time_frame>
    <description>Length of stay in days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Score</measure>
    <time_frame>12 months</time_frame>
    <description>EORTC Thyroid specific Health related quality of life</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Thyroid Diseases</condition>
  <condition>Surgery</condition>
  <arm_group>
    <arm_group_label>TOETVA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transoral Endoscopic Thyroidectomy Vestibular Approach</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TOETVA</intervention_name>
    <description>Transoral Endoscopic Thyroidectomy Vestibular Approach</description>
    <arm_group_label>TOETVA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Patients needing surgery for: Benign or indeterminate nodule less than 6 cm in size or;&#xD;
        T1 well differentiated papillary carcinoma less than 2 cm in size or; Well-controlled&#xD;
        Grave's disease or; Parathyroid adenoma.&#xD;
&#xD;
          -  Total thyroid size is 7-8 cm (no more than 10 cm)&#xD;
&#xD;
          -  Their age is ≥18 years and ≤80 years&#xD;
&#xD;
          -  Able to give written consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  - History of neck surgery or neck radiotherapy&#xD;
&#xD;
          -  Recurrent thyroid disease&#xD;
&#xD;
          -  Lymph node metastases&#xD;
&#xD;
          -  Presence of intraoral infections&#xD;
&#xD;
          -  Presence of extrathyroidal or substernal extensions&#xD;
&#xD;
          -  Smoking&#xD;
&#xD;
          -  Morbid obesity&#xD;
&#xD;
          -  Contra-indication to general anesthesia with nasotracheal intubation&#xD;
&#xD;
          -  Previous mediastinal surgery&#xD;
&#xD;
          -  Any anatomical anomaly that in the opinion of the investigator may render the&#xD;
             intervention more difficult (ex. variations in the structure of the platysmas muscle)&#xD;
&#xD;
          -  Any medical condition, which in the judgment of the investigator and/or designee makes&#xD;
             the subject a poor candidate for the investigational procedure&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jesse D Pasternak, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network, Toronto</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jesse D Pasternak, MD</last_name>
    <phone>14163405195</phone>
    <email>jesse.pasternak@uhn.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Univeristy Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jesse D Pasternak, MD</last_name>
      <phone>4163405195</phone>
      <email>jesse.pasternak@uhn.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>February 19, 2021</study_first_submitted>
  <study_first_submitted_qc>April 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2021</study_first_posted>
  <last_update_submitted>April 11, 2021</last_update_submitted>
  <last_update_submitted_qc>April 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TOETVA</keyword>
  <keyword>Transoral Endoscopic Thyroidectomy Vestibular Approach</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

